Opendata, web and dolomites

CYTOPRO

Profiling of tumour cells in blood for personalized treatment of metastatic cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CYTOPRO project word cloud

Explore the words cloud of the CYTOPRO project. It provides you a very rough idea of what is the project "CYTOPRO" about.

patient    efficient    platform    5bn    innovation    2009    accurate    diagnostic    perfect    device    cells    reduce    routine    cancer    isolate    foothold    prepare    42    10    form    10bn    2m    breast    circulate    assays    metastasised    2013    tool    ctcs    therapy    days    primary    larger    deaths    biased    gaining    shed    trials    patients    personalised    metastatic    single    blood    40    markets    labs    clinicians    worth    clinical    incl    detection    individual    isolation       treatment    diagnosed    fast    vasculature    ctc    tumour    technologies    lives    fail    12    expects    6bn    superior    approaching    alone    circulating    challenge    exact    citizens    43bn    126bn    first    productivity    cheap    medicine    mutation    profile       gt    lose    market    bloodstream    annually    breakthrough    cell    losses    lost    customers    7bn    solution    18    characterisation    cytotrack    worldwide    pathologists    regulatory   

Project "CYTOPRO" data sheet

The following table provides information about the project.

Coordinator
CYTOTRACK APS 

Organization address
address: GAMMEL LUNDTOFTEVEJ 1D
city: LYNGBY
postcode: 2800
website: www.cytotrack.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.cytotrack.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CYTOTRACK APS DK (LYNGBY) coordinator 50˙000.00

Map

 Project objective

Challenge Up to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.

Solution Circulating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.

Impact The innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.

Project This phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.

Customers and market The CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CYTOPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CYTOPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More